{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:43:09Z","timestamp":1790106189607,"version":"4.0.1"},"reference-count":60,"publisher":"Medknow","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0019-5154.110832","type":"journal-article","created":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T09:09:23Z","timestamp":1366448963000},"page":"219","source":"Crossref","is-referenced-by-count":155,"title":["Pharmacology of antihistamines"],"prefix":"10.4103","volume":"58","author":[{"given":"MartinK","family":"Church","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DianaS","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"key":"key-10.4103\/0019-5154.110832-1","first-page":"1089","volume-title":"Introduction to antihistamine agents and antergan derivative","author":"Bovet","year":"1950","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/0019-5154.110832-2","first-page":"818","volume-title":"Action de la thymoxyethyldiethylamine (929F) et des ethers phenoliques sur le choc anaphylactique","author":"Staub","year":"1937","journal-title":"C R Soc Biol"},{"key":"key-10.4103\/0019-5154.110832-3","first-page":"339","volume-title":"Les antihistaminiques de synthese.Essais de chemotherapie des etats allergiques","author":"Halpern","year":"1942","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"key-10.4103\/0019-5154.110832-4","first-page":"229","volume-title":"The anti-histamine properties of benadryl, beta-di-methylaminoethyl benzhydryl ether hydrochloride","author":"Loew","year":"1946","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/0019-5154.110832-5","first-page":"1","volume-title":"Histamine and the antiallergic antihistamines: A history of their discoveries","author":"Emanuel","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/0019-5154.110832-6","first-page":"489","volume-title":"H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects","author":"Leurs","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/0019-5154.110832-7","first-page":"29994","volume-title":"Mutational analysis of the antagonist-binding site of the histamine H (1) receptor","author":"Wieland","year":"1999","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0019-5154.110832-8","first-page":"391","volume-title":"Binding characteristics of cetirizine and levocetirizine to human H (1) histamine receptors: Contribution of Lys (191) and Thr (194)","author":"Gillard","year":"2002","journal-title":"Mol Pharmacol"},{"key":"key-10.4103\/0019-5154.110832-9","first-page":"121","volume-title":"The role of histamine and the tuberomamillary nucleus in the nervous system","author":"Haas","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"key-10.4103\/0019-5154.110832-10","first-page":"637","volume-title":"The physiology of brain histamine","author":"Brown","year":"2001","journal-title":"Prog Neurobiol"},{"key":"key-10.4103\/0019-5154.110832-11","first-page":"2203","volume-title":"Advances in H1-antihistamines","author":"Simons","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-5154.110832-12","first-page":"S390","volume-title":"Clinical outcomes and adverse effect monitoring in allergic rhinitis","author":"Juniper","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-13","first-page":"715","volume-title":"The hypnotic effects of an antihistamine: Promethazine","author":"Adam","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/0019-5154.110832-14","first-page":"1343","volume-title":"Allergy medication in Japanese volunteers: Treatment effect of single doses on nocturnal sleep architecture and next day residual effects","author":"Boyle","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/0019-5154.110832-15","first-page":"291","volume-title":"The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats","author":"Rojas-Zamorano","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0019-5154.110832-16","first-page":"2350","volume-title":"Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance","author":"Kay","year":"1997","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/0019-5154.110832-17","first-page":"459","volume-title":"Risk of first-generation H (1)-antihistamines: A GA (2) LEN position paper","author":"Church","year":"2010","journal-title":"Allergy"},{"key":"key-10.4103\/0019-5154.110832-18","first-page":"1305","volume-title":"Consensus Group on New-Generation Antihistamines (CONGA): Present status and recommendations","author":"Holgate","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/0019-5154.110832-19","first-page":"1427","volume-title":"EAACI\/GA (2) LEN\/EDF\/WAO guideline: Management of urticaria","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"key-10.4103\/0019-5154.110832-20","first-page":"9","volume-title":"Histamine, but not leukotriene C4, is an essential mediator in cold urticaria wheals","author":"Nuutinen","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/0019-5154.110832-21","first-page":"284","volume-title":"Histamine is released in the wheal but not the flare following challenge of human skin in vivo: A microdialysis study","author":"Petersen","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/0019-5154.110832-22","first-page":"73","volume-title":"How minimally invasive is microdialysis sampling.A cautionary note for cytokine collection in human skin and other clinical studies?","author":"Stenken","year":"2010","journal-title":"AAPS J"},{"key":"key-10.4103\/0019-5154.110832-23","first-page":"317","volume-title":"Unmet clinical needs in chronic spontaneous urticaria.A GA\u00b2LEN task force report","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"key-10.4103\/0019-5154.110832-24","first-page":"459","volume-title":"Chronic urticaria: Assessment of current treatment","author":"Wedi","year":"2005","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-25","first-page":"631","volume-title":"BSACI guidelines for the management of chronic urticaria and angio-oedema","author":"Powell","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/0019-5154.110832-26","first-page":"399","volume-title":"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans","author":"Molimard","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"key-10.4103\/0019-5154.110832-27","first-page":"367","volume-title":"Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines","author":"Gillard","year":"2005","journal-title":"Inflamm Res"},{"key":"key-10.4103\/0019-5154.110832-28","first-page":"190","volume-title":"A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects","author":"Grant","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key-10.4103\/0019-5154.110832-29","first-page":"424","volume-title":"Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin","author":"Denham","year":"2003","journal-title":"Inflamm Res"},{"key":"key-10.4103\/0019-5154.110832-30","first-page":"635","volume-title":"Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours","author":"Purohit","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key-10.4103\/0019-5154.110832-31","first-page":"355","volume-title":"Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years","author":"Simons","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-32","first-page":"1551","volume-title":"Relevance of H1-receptor occupancy to H1-antihistamine dosing in children","author":"Simons","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-33","first-page":"388","volume-title":"Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin","author":"Purohit","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/0019-5154.110832-34","first-page":"387","volume-title":"Twenty-four hours of activity of cetirizine and fexofenadine in the skin","author":"Purohit","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key-10.4103\/0019-5154.110832-35","first-page":"69","volume-title":"Clinical pharmacokinetics of fexofenadine enantiomers","author":"Miura","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key-10.4103\/0019-5154.110832-36","first-page":"217","volume-title":"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: A comparative review","author":"Devillier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/0019-5154.110832-37","first-page":"179","volume-title":"P-Glycoprotein, a gatekeeper in the blood-brain barrier","author":"Schinkel","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"key-10.4103\/0019-5154.110832-38","first-page":"312","volume-title":"P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists","author":"Chen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"key-10.4103\/0019-5154.110832-39","first-page":"866","volume-title":"OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine","author":"Cvetkovic","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"key-10.4103\/0019-5154.110832-40","first-page":"890","volume-title":"Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography","author":"Tashiro","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/0019-5154.110832-41","first-page":"133","volume-title":"An evaluation of the effects of high-dose fexofenadine on the central nervous system: A double-blind, placebo-controlled study in healthy volunteers","author":"Hindmarch","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/0019-5154.110832-42","first-page":"540","volume-title":"Dose dependency of brain histamine H (1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C] doxepin","author":"Tashiro","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"key-10.4103\/0019-5154.110832-43","first-page":"617","volume-title":"Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis","author":"Meltzer","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-44","first-page":"927","volume-title":"Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis","author":"Howarth","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-45","first-page":"573","volume-title":"Loratadine versus cetirizine: Assessment of somnolence and motivation during the workday","author":"Salmun","year":"2000","journal-title":"Clin Ther"},{"key":"key-10.4103\/0019-5154.110832-46","first-page":"1184","volume-title":"Sedation with \"non-sedating\" antihistamines: Four prescription-event monitoring studies in general practice","author":"Mann","year":"2000","journal-title":"BMJ"},{"key":"key-10.4103\/0019-5154.110832-47","first-page":"221","volume-title":"Non-interventional study comparing treatment satisfaction in patients treated with antihistamines","author":"De","year":"2008","journal-title":"Clin Drug Investig"},{"key":"key-10.4103\/0019-5154.110832-48","first-page":"109","volume-title":"Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)","author":"Day","year":"2004","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/0019-5154.110832-49","first-page":"233","volume-title":"Cardiac actions of antihistamines","author":"Woosley","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key-10.4103\/0019-5154.110832-50","first-page":"429","volume-title":"H (1) antihistamine drug promethazine directly blocks hERG K(+) channel","author":"Jo","year":"2009","journal-title":"Pharmacol Res"},{"key":"key-10.4103\/0019-5154.110832-51","first-page":"104","volume-title":"Blockade of HERG K+channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656","author":"Park","year":"2008","journal-title":"J Appl Toxicol"},{"key":"key-10.4103\/0019-5154.110832-52","first-page":"1168","volume-title":"Electrocardiographic findings in patients with diphenhydramine overdose","author":"Zareba","year":"1997","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/0019-5154.110832-53","first-page":"119","volume-title":"Safety of antihistamines in children","author":"Ten","year":"2001","journal-title":"Drug Saf"},{"key":"key-10.4103\/0019-5154.110832-54","first-page":"281","volume-title":"Second-generation antihistamines: The risk of ventricular arrhythmias","author":"DuBuske","year":"1999","journal-title":"Clin Ther"},{"key":"key-10.4103\/0019-5154.110832-55","first-page":"617","volume-title":"Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis","author":"Simons","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-56","first-page":"1011","volume-title":"Levocetirizine does not prolong the QT\/QTc interval in healthy subjects: Results from a thorough QT study","author":"Hulhoven","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/0019-5154.110832-57","first-page":"38S","volume-title":"Comparative pharmacology of H1 antihistamines: Clinical relevance","author":"Simons","year":"2002","journal-title":"Am J Med"},{"key":"key-10.4103\/0019-5154.110832-58","first-page":"777","volume-title":"Clinical pharmacology of H1-antihistamines in the skin","author":"Simons","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0019-5154.110832-59","first-page":"249","volume-title":"Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: A randomized clinical trial","author":"Shohrati","year":"2007","journal-title":"Cutan Ocul Toxicol"},{"key":"key-10.4103\/0019-5154.110832-60","first-page":"437","volume-title":"H1-antihistamines in children","author":"Simons","year":"2002","journal-title":"Clin Allergy Immunol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T15:51:21Z","timestamp":1392997881000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.e-ijd.org\/text.asp?2013\/58\/3\/219\/110832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"alternative-id":["110832"],"URL":"https:\/\/doi.org\/10.4103\/0019-5154.110832","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}